15 July 2025 - Eli Lilly Canada announced today that Health Canada has approved Omvoh (mirikizumab) for Crohn's disease, which will soon be available to patients in Canada. 

Omvoh is an interleukin-23p19 antagonist for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment.

Health Canada has also approved a new citrate-free formulation of Omvoh for subcutaneous injection, for the existing ulcerative colitis indication, as well as the new Crohn's disease indication.

Read Eli Lilly press release